BioNTech Results Presentation Deck
iNeST I Autogene Cevumeran (BNT122)
Phase 1 for Adjuvant Treatment of Pancreatic Cancer
20
Vaccine-induced Neoantigen-specific immune responses of high magnitude against at least one of the neoantigens by ex vivo
IFNY ELISPOT in half of the patients.
Prolonged Relapse free survival in patients who have high magnitude Immune responses.
Number of neoantigens in
autogene cevumeran
20
15-
0
Responders
(n=8)
Non-responders
(n=8)
iNeST is being developed in collaboration with Genentech.
RFS, recurrence-free survival
Immunogenic
Non-immunogenic
No data
Balachandran VP, et al. ASCO Annual Meeting 2022; Poster presentation 2516.
Investor-initiated single-center study sponsored by Memorial Sloan Kettering Cancer Center
IFNy spots x 10 cells
1000
100
10
0
Responders
(n=8)
0
*
20 40 60 80
Weeks after surgery
*Patient treated in non-protocol-specified sequence
100
100
RFS (%)
50
O
No. at risk
8
Responder
Non-responder 8
00 00
IL
Median RFS: Not reached
Median RFS: 13.7 months
T
12 18 24
Time (months)
(O
6
8
COCO
6
7
5
62
ON
2
RFS from resection (n=16)
1
30
00
BIONTECHView entire presentation